Sonosite Files Registration Statement for Public Offering

February 22, 2002

BOTHELL, WA, February 22, 2002 - Sonosite, Inc. (Nasdaq: SONO), today announced the filing with the Securities and Exchange Commission, or SEC, of a registration statement for a proposed public offering of 2,700,000 shares of its common stock. All of the shares will be offered by Sonosite. UBS Warburg LLC and Deutsche Banc Alex. Brown will serve as managing underwriters for the offering. Sonosite has granted the underwriters an option to purchase up to an additional 405,000 shares to cover any over-allotments. Copies of the preliminary prospectus relating to this offering are not yet available.

When available, they may be obtained from UBS Warburg LLC, Prospectus Department, 299 Park Avenue, New York, New York 10171, telephone: (212) 821-3000. Sonosite, Inc. (, headquartered in Bothell, WA, is a leading provider of high performance, highly miniaturized, hand-carried, all-digital ultrasound devices for use in a variety of clinical applications and settings. A registration statement relating to these securities has been filed with the SEC but has not yet become effective.

These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Sonosite
Sonosite, Inc. ( is the innovator and world leader in hand-carried ultrasound, with an installed base of more than 20,000 systems. The Company, headquartered near Seattle, Washington is represented by eight subsidiaries and a global distribution netwok in over 75 countries. Sonosite's small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The Company employs approximately 450 people worldwide.